HIV meds just four days a week?

And other conference highlights including new long-acting drug GS-6207; PrEP on demand; HIV treatment = prevention.
By

Building blocks for a healthy life

Building blocks for a healthy life, with insights from a nurse educator
By John J. Parisot, PhD, MSN, RN

Briefly

Editor's Note

Note to my younger self
By

Truvada Safety

Talking about PrEP and HIV treatment in a time of class action lawsuits
By Cori Blum, MD, AAHIVS​​​​​​​

Briefly

By

Healthiness in HIV

A look in the poster hall
By

Drugs in development

Monthly injections plus inhibitors of viral capsid and maturation
By

Briefly: May+June 2019

FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)

It's the first, once-daily, single-tablet, two-drug regimen for treatment-naïve HIV-1 adults
Subscribe to HIV Treatment